Mapping from (not specified) to (not specified)

DRAFT. Published on 2023-07-14T15:38:26Z by National Association of Community Health Centers, Inc. (NACHC) ( https://www.nachc.org/ ). Copyright National Association of Community Health Centers, Inc. (NACHC)

Group 1 Mapping from Extended Codes CodeSystem to http://www.ama-assn.org/go/cpt

Source Code	Relationship	Target Code
NACHC.B2.DE103 (Antinuclear antibodies (ANA))	is equivalent to	86038 (Antinuclear antibodies (ANA))
NACHC.B2.DE104 (Hepatitis C antibody)	is equivalent to	86803 (Hepatitis C antibody)
NACHC.B2.DE105 (Hepatitis C antibody; confirmatory test (eg, immunoblot))	is equivalent to	86804 (Hepatitis C antibody; confirmatory test (eg, immunoblot))
NACHC.B2.DE106 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique)	is equivalent to	87520 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique)
NACHC.B2.DE107 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed)	is equivalent to	87521 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed)
NACHC.B2.DE108 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed)	is equivalent to	87522 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed)
NACHC.B2.DE109 (Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus)	is equivalent to	87902 (Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus)
NACHC.B2.DE113 (RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C))	is equivalent to	3218F (RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C))
NACHC.B2.DE114 (Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C))	is equivalent to	3220F (Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C))
NACHC.B2.DE115 (Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C))	is equivalent to	3265F (Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C))
NACHC.B2.DE116 (Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C))	is equivalent to	3266F (Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C))
NACHC.B2.DE117 (Hepatitis C screening documented as performed (HIV))	is equivalent to	3514F (Hepatitis C screening documented as performed (HIV))
NACHC.B2.DE118 (Patient receiving antiviral treatment for Hepatitis C (HEP-C))	is equivalent to	4150F (Patient receiving antiviral treatment for Hepatitis C (HEP-C))
NACHC.B2.DE119 (Collection of venous blood by venipuncture)	is equivalent to	36415 (Collection of venous blood by venipuncture)
NACHC.B2.DE120 (Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver)	is equivalent to	81596 (Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver)